Kodiak Sciences Inc
Pagina dedicata companiei Kodiak Sciences Inc listata cu simbolul US.KOD
Descriere companie[edit | ]
Kodiak Sciences Inc. (www.kodiak.com) is a biopharmaceutical company. The Company is focused on researching, developing, and commercializing transformative therapeutics to treat high prevalence retinal diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. Its lead product candidate, KSI-301, is a anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age related macular degeneration, a leading cause of blindness in elderly patients, and diabetic eye diseases, a leading cause of blindness in working-age patients. The Company has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor Trap-Antibody-Fusion, bioconjugate molecule designed to target concurrent inflammation and abnormal angiogenesis observed in the pathogenesis of retinal vascular diseases.
Grafic actiuni companie[edit | ]